Tuesday, April 3, 2018

What Is A Hepatologist ? What Is A Gastroenterologist?

Links 2018
Fatty Liver
Watch videos, or review research in this current collection of articles

Non-invasive test to measure liver inflammation and fibrosis.
FibroScan® Scoring Card - Understanding The Results

Hepatitis C
Newly Diagnosed
FDA Approved Drugs To Treat Hepatitis C
Treating HCV according to genotype

What Is A Hepatologist ? What Is A Gastroenterologist?
The study of gastroenterology and hepatology are often related to each other. A gastroenterologist is an internist who has completed specialty training in the treatment of digestive disorders. Digestive disorders include disorders of the esophagus, stomach, small and large intestines, pancreas, gallbladder, and liver.

In order to become board certified in gastroenterology, the doctor must first become board certified in internal medicine. In order to become eligible to even take the examination for board certification in gastroenterology, a gastrointestinal (GI) fellowship lasting an additional two to three years beyond an internal medicine residency must be completed.

During the course of their two to three years of training in gastroenterology, some gastroenterologists have little exposure to patients with liver disease.

On the other hand, some gastroenterologists have a great deal of exposure to patients with liver disease during the course of their gastroenterology specialty training.

Thus, the level of experience and expertise among gastroenterologists in diagnosing and treating liver disease varies greatly. It is important for the patient to determine the gastroenterologist's level of expertise in liver disease prior to establishing a long-term medical relationship with this type of doctor.

Clinical hepatology generally deals with the liver, its functions and its diseases. Most disorders of the liver are usually grouped together under hepatology. Examples of these diseases are liver cirrhosis, hemochromatosis, and hepatitis. Hepatitis is liver inflammation brought about by infection with several types of hepatitis virus, which include the hepatitis A virus and the hepatitis C virus, among many others.

What Is A Hepatologist ?
A hepatologist is the most experienced and qualified type of doctor to treat people with liver disease. Since there is currently no separate board certification examination in the field of hepatology, there is no official definition of a hepatologist. However, there are specialized training programs for doctors who are focused solely on liver disease. These are known as hepatology fellowships and typically last from one to two years. Over the course of a hepatology fellowship, a doctor receives comprehensive training in the diagnosis and treatment of liver disease. This specialty training typically includes extensive exposure to all liver diseases, including those that are rare and infrequently seen. This intense training in liver disease is rarely matched in a gastroenterology fellowship

A physician who successfully completes a hepatology fellowship is considered a hepatologist. Most hepatologists, although not all, are also gastroenterologists. These doctors have successfully completed both a hepatology and a gastroenterology fellowship. Occasionally, gastroenterologists who have not completed a fellowship in hepatology nonetheless focus their medical practice primarily on the diagnosis and treatment of people with liver disease. While these physicians do not have a separate diploma in the field of liver disease, they may also be considered hepatologists.

For many reasons, it is to the patient’s advantage to choose a hepatologist to treat his liver disease. The patient can be virtually assured that the hepatologist will have substantial experience in the diagnosis and treatment of the full range of liver diseases. Furthermore, hepatologists are likely to be the first to learn about the most up-to-date therapies—both FDA-approved and experimental—and to incorporate them into their practices. However, whether someone chooses to see a gastroenterologist or a hepatologist, it is important to find a doctor who is willing to work with him as an equal partner in the healing process.

What is a Gastroenterologist?
A Gastroenterologist is a physician with dedicated training and unique experience in the management of diseases of the gastrointestinal tract and liver.

What is Gastroenterology?
Gastroenterology is the study of the normal function and diseases of the esophagus, stomach, small intestine, colon and rectum, pancreas, gallbladder, bile ducts and liver. It involves a detailed understanding of the normal action (physiology) of the gastrointestinal organs including the movement of material through the stomach and intestine (motility), the digestion and absorption of nutrients into the body, removal of waste from the system, and the function of the liver as a digestive organ. It includes common and important conditions such as colon polyps and cancer, hepatitis, gastroesophageal reflux (heartburn), peptic ulcer disease, colitis, gallbladder and biliary tract disease, nutritional problems, Irritable Bowel Syndrome (IBS), and pancreatitis. In essence, all normal activity and disease of the digestive organs is part of the study of Gastroenterology.

What do all the letters after your doctor’s name mean?
Some Gastroenterologists receive special recognition from national societies when they demonstrate extraordinary achievement in research, teaching, or other unique service to the field of Gastroenterology. The American College of Gastroenterology and the American College of Physicians designate such physicians as “Fellows” and the suffixes FACG and FACP are added to denote these honors. This means that these physicians have fulfilled the respective organizations’ rigorous requirements to gain this added distinction

What makes Gastroenterologists different?
The unique training that Gastroenterologists complete provides them with the ability to provide high quality, comprehensive care for patients with a wide variety of gastrointestinal ailments. Gastroenterologists perform the bulk of research involving gastrointestinal endoscopic procedures as well as the interpretation of results, and are considered experts in the field. Studies have shown that Gastroenterologists perform higher quality colonoscopy examinations and comprehensive consultative services when compared to other physicians. This translates into more accurate detection of polyps and cancer by colonoscopy when performed by Gastroenterologists, fewer complications from procedures and fewer days in the hospital for many gastrointestinal conditions managed by trained gastroenterology specialists. It is this ability to provide more complete, accurate, and thorough care for patients with gastrointestinal conditions, which distinguishes Gastroenterologists

The Training
Gastroenterology fellowship training is an intense, rigorous program where future Gastroenterologists learn directly from nationally recognized experts in the field and develop a detailed understanding of gastrointestinal disA Gastroenterologist must first complete a three-year Internal Medicine residency and is then eligible for additional specialized training (fellowship) in Gastroenterology. This fellowship is generally 2-3 years long so by the time Gastroenterologists have completed their training, they have had 5-6 years of additional specialized education

They learn how to evaluate patients with gastrointestinal complaints, treat a broad range of conditions, and provide recommendations to maintain health and prevent disease. They learn to care for patients in the office as well as in the hospital.

Gastroenterologists also receive dedicated training in endoscopy (upper endoscopy, sigmoidoscopy, and colonoscopy) by expert instructors. Endoscopy is the use of narrow, flexible lighted tubes with built-in video cameras, to visualize the inside of the intestinal tract. This specialized training includes detailed and intensive study of how and when to perform endoscopy, optimal methods to complete these tests safely and effectively, and the use of sedating medications to ensure the comfort and safety of patients. Gastroenterology trainees also learn how to perform advanced endoscopic procedures such as polypectomy (removal of colon polyps), esophageal and intestinal dilation (stretching of narrowed areas), and hemostasis (injection or cautery to stop bleeding). Importantly, Gastroenterologists learn how to properly interpret the findings and biopsy results of these studies in order to make appropriate recommendations to treat conditions and/or prevent cancer

Some Gastroenterologists also receive directed training in advanced procedures using endoscopes such as endoscopic biliary examination (endoscopic retrograde cholangiopancreatography or ERCP), removal of tumors without surgery (endoscopic mucosal resection or EMR), placement of internal drainage tubes (stents) and endoscopic ultrasound (EUS). This provides them with the training necessary to non-surgically remove stones in the bile ducts, evaluate and treat tumors of the gastrointestinal tract and liver, and provide minimally invasive alternatives to surgery for some patients

The most critical emphasis during the training period is attention to detail and incorporation of their comprehensive knowledge of the entire gastrointestinal tract to provide the highest quality endoscopy and consultative services

The final product is a highly trained specialist with a unique combination of broad scientific knowledge, general Internal Medicine training, superior endoscopic skills and experience, and the ability to integrate these elements to provide optimal health care for patients. This advanced fellowship training is overseen by national societies committed to ensuring high quality and uniform education. These groups include the American Board of Internal Medicine, the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. These groups carefully scrutinize the educational experience of each program to ensure that every Gastroenterology trainee receives the highest quality training. Once fellows successfully complete their training they are considered “Board Eligible.” They are then qualified to take the Gastroenterology board certification test administered by the American Board of Internal Medicine. Once they have successfully completed this examination they are “Board Certified.” FACG, FACP —

Aside from diagnosing and treating patients with gastrointestinal problems, gastroenterology and hepatology specialists also usually conduct research. Most of this research is directed at finding newer methods to detect gastrointestinal diseases and prevent their development. These doctors also search for new and better drugs to be used for the treatment of gastroenterology and hepatology patients.
Source

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis

BMJ Gastroenterology
Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis 
Sally Ann Tran1, An Le1, Changqing Zhao2, Joseph Hoang1, Lee Ann Yasukawa3, Susan Weber3,
Linda Henry1, Mindie H Nguyen1

Full-Text Available Online:

Abstract
Background In patients with chronic hepatitis C (CHC) cirrhosis, imaging for hepatocellular carcinoma (HCC) is recommended every 6 months to maximise eligibility for curative treatment. The aim was to determine the adherence rate and outcomes among patients with CHC cirrhosis and whether the adherence rate has improved over time.

Methods
Retrospective cohort study of patients with CHC cirrhosis (n=2366) monitored for ≥1 year at Stanford University Medical Center between January 2001 and August 2015.

Results
Overall demographics: mean age 54; 62.3% men; 48.3% Caucasian. 24.4% adherent to imaging every 6 months per European Association for the Study of the Liver 2000 and American Association for the Study of Liver Diseases (AASLD) 2011 criteria and 44% at least every 12 months per AASLD 2005 criteria. No significant change in adherence before and after 2011. Predictors of multivariable analysis of adherence were age >54 (OR 1.74, p<0.0001), Asian ethnicity (OR 2.23, p<0.0001), liver decompensation (OR 2.40, p<0.0001) and having ≥2 clinical visits per year (OR 1.33, p=0.01). During follow-up, 9.6% were diagnosed with HCC. Adherent patients were more likely to have smaller tumours (2.3 vs 3.3 cm, p=0.0020), be within the Milan criteria for liver transplants (73.2% vs 54.8%, p=0.006) and receive curative HCC treatment (43.6% vs 24.0%, p=0.005). On multivariable analysis, curative treatment (HR 0.32, p=0.001) and every 6-month imaging (HR 0.34, p=0.005), but not every 6–12 month imaging, were associated with reduced risk of mortality.

Conclusions
Adherence to HCC surveillance continues to be poor. Adherent patients with HCC were more likely to undergo curative treatment and have better survival. Research understanding barriers to surveillance is needed.

Summary box
What is already known about this subject?
Major liver disease societies recommend surveillance for hepatocellular carcinoma (HCC) in high-risk groups to maximise eligibility for curative treatment.

The American Association for the Study of Liver Diseases (AASLD) 2011 and European Association for the Study of the Liver (EASL) 2000 guidelines recommend HCC surveillance every 6 months.

The AASLD 2005 guideline recommends surveillance every 12 months.

What are the new findings?
In a large, real-life cohort of patients with chronic hepatitis C cirrhosis, only 24% underwent HCC surveillance every 6 months and only 44% had surveillance at least every 12 months.

Adherence rates remained poor over the 16 years of the study: the every 6 month surveillance rate was 20.5% before 2011 and 21.6% after 2011 (p=0.21).

The 5-year cumulative survival was 54.7% for the adherent (every 6-month imaging) group, compared with 6.5% for the non-adherent group (p<0.00001). Although every 6-month imaging reduced mortality by 66%, every 6–12 month imaging did not.

Besides age >54, Asian ethnicity and decompensation, more frequent clinic visits was associated with a 33% increase in every 6-month imaging.

How might it impact on clinical practice in the foreseeable future?
Further research to understand barriers to surveillance is needed, but our study suggests that just one additional clinic visit per year increases the likelihood of undergoing surveillance.

Continue reading Online.....

MAVIRET (Glecaprevir/pibrentasvir) treats hepatitis C in HIV-coinfected individuals

Glecaprevir/pibrentasvir treats hepatitis C in HIV-coinfected individuals
Last Updated: 2018-04-02
By Reuters Staff
NEW YORK (Reuters Health) - The direct-acting antiviral (DAA) combination glecaprevir/pibrentasvir is effective for treating hepatitis C virus (HCV) infection in individuals coinfected with HIV-1, according to results from the non-randomized, open-label phase 3 EXPEDITION-2 trial. As many as 3 million of the 80 million individuals infected with HCV worldwide are coinfected with HIV-1. Most guidelines recommend these patients be treated like those with HCV monoinfection, with careful monitoring for drug-drug interactions with antiretroviral therapy (ART)....
Continue reading article: http://www.chronicliverdisease.org/reuters/article.cfm?article=20180402Other1554755267

Cocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for Hepatitis C

Cocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C Virus

ATLANTA, GA and BOTHELL, WA, April 03, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses and noroviruses, announced today that its Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) is now open and the Company is cleared to initiate its Phase 2a clinical study evaluating CC-31244 for the treatment of hepatitis C virus (“HCV”) infected individuals.

Gary Wilcox, Vice Chairman and Interim Chief Executive Officer of Cocrystal, commented, “The achievement of this regulatory milestone is a significant step forward in the advancement of our lead program, CC-31244. Based on the positive results from our Phase 1a/1b study, we believe that CC-31244 has the potential to change the treatment paradigm for patients living with HCV providing a shorter therapy with existing HCV combination therapies and a substantial and durable antiviral effect. We look forward to further evaluating the effect of CC-31244 and the commencement of this next phase of clinical development.”

CC-31244, the Company’s lead product in development, is an investigational, oral, highly potent, broad-spectrum non-nucleoside inhibitor with high barrier to drug resistance designed and developed using the Company's proprietary structure-based drug discovery technology. CC-31244 is active against all six HCV genotypes, with low level cytotoxicity in multiple cell types.

The Phase 2a study is an open-label study designed to evaluate the safety, tolerability and preliminary efficacy of CC-31244 with approved HCV drugs. Endpoints of the Phase 2a study include changes in HCV RNA viral load, adverse events and laboratory abnormalities. Cocrystal expects to commence its Phase 2a study of CC-31244 in the second quarter of 2018 and announce data in the fourth quarter of this year.

In August 2017, the Company announced positive data from the Phase 1a/1b trial of CC-31244 for the treatment of chronic hepatitis C infection. This randomized, placebo-controlled, double-blind Phase 1a/1b study evaluated single and multiple ascending doses of CC-31244 for safety/tolerability, pharmacokinetics, and antiviral activity in healthy volunteers and patients with HCV infection. In Phase 1a, 30 healthy volunteers received single doses (20-400 mg) of CC-31244, and 12 healthy volunteers received repeated doses of CC-31244 (either 200 or 400 mg) for 7 days. In Phase 1b, 15 patients with HCV genotype-1 infection received CC-31244 for 7 days (6, 400 mg daily; 6, 600 mg daily; 3, 200 mg twice daily). Eighteen subjects received placebo during the study.

As reported, there were no dose-limiting adverse events, study discontinuations due to adverse events, or serious adverse events. Viral load data showed that CC-31244 administered once daily (400 mg or 600 mg) or twice daily (200 mg) for 7 days had a substantial and durable antiviral effect, with an average HCV RNA viral load decline from baseline of 1000-fold by Day 4. Interestingly, the average viral load at 6 days after the last dose persisted in the range of 100-fold below baseline. HCV genotype 1b cell-based replicon assays using combinations of CC-31244 with other classes of HCV drugs showed additive and synergistic effects of CC-31244, providing important information for ultra-short therapy cocktail regimens.

Monday, April 2, 2018

NASH / NAFLD - MediciNova Announces Phase 2 Trial of MN-001 will be Terminated Early based on Significant Positive Results from Interim Analysis

MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis

LA JOLLA, Calif., April 01, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will terminate the Phase 2 clinical trial of MN-001 (tipelukast) in NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) with hypertriglyceridemia early based on the significant positive results from an interim analysis.

MN-001 (tipelukast) significantly reduced mean serum triglycerides, a primary endpoint, from 260.1 mg/dL before treatment to 185.2 mg/dL after eight weeks of treatment (p=0.00006). There were no clinically significant safety or tolerability issues during the study. Having achieved the most important endpoint of the study, MediciNova will discontinue enrollment and stop the study in order to accelerate further development of MN-001.

Details of this interim analysis will be presented at the International Liver Congress 2018, the 53rd annual meeting of the European Association for the Study of the Liver (EASL), during the NAFLD: Therapy poster session on Friday, April 13, 2018 in Paris, France.

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are thrilled with the results of this study, which showed a large reduction in triglycerides. Based on the results of this study, along with the triglyceride data we have from prior clinical studies of MN-001 in other indications, we believe that MN-001 has potential to benefit a wide range of patients with hypertriglyceridemia, not limited to those with NASH and NAFLD.”

MN-001 (tipelukast) significantly reduced mean serum triglycerides, a primary endpoint, from 260.1 mg/dL before treatment to 185.2 mg/dL after eight weeks of treatment (p=0.00006). There were no clinically significant safety or tolerability issues during the study. Having achieved the most important endpoint of the study, MediciNova will discontinue enrollment and stop the study in order to accelerate further development of MN-001.MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will terminate the Phase 2 clinical trial of MN-001 (tipelukast) in NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) with hypertriglyceridemia early based on the significant positive results from an interim analysis.

Details of this interim analysis will be presented at the International Liver Congress 2018, the 53rd annual meeting of the European Association for the Study of the Liver (EASL), during the NAFLD: Therapy poster session on Friday, April 13, 2018 in Paris, France.

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are thrilled with the results of this study, which showed a large reduction in triglycerides. Based on the results of this study, along with the triglyceride data we have from prior clinical studies of MN-001 in other indications, we believe that MN-001 has potential to benefit a wide range of patients with hypertriglyceridemia, not limited to those with NASH and NAFLD.”

About the Trial

The Phase 2a trial is a multi-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in subjects with non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia. Eligible subjects consisted of males and females ranging in age from 21 to 65 years old, inclusive. To be eligible, subjects must have had a histologically confirmed diagnosis of NASH or imaging study confirmed NAFLD and an elevated serum triglyceride (>150 mg/dL) during the Screening Phase.

About MN-001

MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (progressive MS), amyotrophic lateral sclerosis (ALS) and substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova’s pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbations of asthma and MN-029 (denibulin) for solid tumor cancers. MediciNova is engaged in strategic partnering and other potential funding discussions to support further development of its programs. For more information on MediciNova, Inc., please visit www.medicinova.com.

Hepatitis Victoria Podcast: Eating for a healthy liver

Hepatitis Victoria Podcast: Nutrition and liver health
Connect On: Facebook
Follow On: Twitter 
Follow: Hepatitis Victoria and others on SoundCloud.

Nutrition and liver health with dietitian Priscilla Hiromi Correa
March 31, 2018
Priscilla Hiromi Correa is a Brazilian dietitian with a special interest in the liver and people living with liver disease. Mark Pearce, Hepatitis Victoria's Communications Manager, spoke with her on a recent visit to our offices. She recommends against 'fad' diets and is in favour of eating based on Australia's dietary recommendations, for optimum liver and general overall health. "Nutrition is so important that through a better diet a patient might even be removed from the transplant waiting list," she says. All Priscilla's recommendations come with a caveat for listeners; consult with your health practitioner about your personal circumstances before following any advice.

The direct-acting virals revolutionized the treatment of hepatitis C


Take a Bow, Pharma, for the Hepatitis C Drugs
March 28, 2018

The direct-acting virals revolutionized the treatment of hepatitis C. They also ushered turbocharged pricing. At least patients—and society—got a major health benefit in return.

The change in hepatitis C treatment is undeniably phenomenal. “Taking out interferon was a huge deal from a side effect perspective,” says Andrew Muir, MD, the gastroenterology chief at Duke, and chair of AASLD’s hepatitis C interest group.

Other benefits include having several treatment choices to pick from, he says, in contrast to when the interferon and ribavirin combination was the only option. Patients with hepatitis C tend to have a wide range of liver, renal, and cardiac comorbidities. Many were ineligible for interferon therapy, so they were, in effect, forced to live with hepatitis C. “Now, it is gratifying to be able take it off their plate,” Muir says.

Sunday, April 1, 2018

2018 - Peeps Diorama Contest

2018 - Peeps Diorama Contest
Who doesn't love Peeps, Happy Easter! In the spirit of Easter this post is all about "Peeps Diorama Contest" taking place in a few cities near you.

To get in the mood check out "PEEPS DIORAMAS COMPILATION" featuring creative scenes starring those little marshmallow bunnies.

Uploaded By: The Sweeter Side



And The Winner Is..............

Washington City Paper
The Peeps diorama contest is supposed to celebrate the very best of the District: creativity and spring. Our contestants did their part, bringing us delightful dioramas inspired by the Oscars, Obamas, and art history. We present the winners of our second annual Peeps diorama contest.


Twin Cities Pioneer Press
Now in its 15th year, the contest that began as a way to have a little fun with these love-’em-or-hate-’em seasonal sugar critters has inspired the world to see the Peep as a muse (we’ve received entries from as far away as Paris and New Zealand). These marshmallow bunnies and chicks represent an annual opportunity for us to gauge the Peepgeist of the day in politics, pop culture, sports, literature, celebrity and news headlines, as well as odes to history, seasons and, always, life in Minnesota.

Racine Art Museum
Within the pristine white walls of this award-winning contemporary art museum, RAM presents an untraditional exhibition showcasing fluffy, sugar-coated marshmallow PEEPS®. The show features 126 entries that demonstrate the talent of over 174 artists.
View Gallery

American Bar Association
2018 Peeps in Law: Stranger Peeps!
The entries are in and we’re down to five finalists!

Video: Peeps In Law




The sticky, sugary history of Peeps
By Tanya Pai
In 2006, the Washington Post launched an annual "Peep Show" diorama contest, asking entrants to create a 3D scene in which all the characters are Peeps. The contest sometimes drew several hundred participants, whose submissions ranged from a Peep van Gogh to a Peepified scene from the movie Up. (You can see past winners of the diorama contest here.) The competition was such a cult favorite that when in 2017 the Post decided to discontinue it, the fine folks at Washington City Paper took it upon themselves to keep the tradition going. (You can see the winners of 2018’s contest online, including an ode to this year’s Best Picture winner titled “The Shape of Sugar.”)
Read the article @ Vox

Until next time,
Tina